Evofem Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Evofem Biosciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-12.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-12.0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: EVFM şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: EVFM şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Evofem Biosciences Piyasaya Karşı Temettü Getirisi

EVFM temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (EVFM)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (EVFM) (3 yıla kadar)	n/a

Önemli Temettü: EVFM şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, EVFM şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: EVFM şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: EVFM herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Evofem Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Evofem Biosciences, Inc. announced that it has received $2.28 million in funding from Aditxt, Inc.

Evofem Biosciences, Inc. announced that it has received $0.46 million in funding from Aditxt, Inc.

Evofem Biosciences Receives Written Notice from the OTC Markets Group Due to Non-Compliance with Minimum Bid Price Requirement for Continued Listing on OTCQB Venture Market

Aditxt, Inc. (NasdaqCM:ADTX) entered into an agreement and plan of merger to acquire Evofem Biosciences, Inc. (OTCPK:EVFM) from shareholders.

Evofem Biosciences, Inc. Provides Sales Guidance for the Third Quarter of 2023

Evofem Biosciences, Inc., Annual General Meeting, Sep 14, 2023

Evofem Biosciences, Inc. announced delayed 10-Q filing

Evofem Biosciences, Inc. Receives Paragraph IV Certification Notice Letter from Padagis Israel Pharmaceuticals Ltd

Evofem Biosciences, Inc. Announces Resignation of Jenny Yip as Member of Board of Director

Evofem Biosciences, Inc. Appoints Justin J. File as Secretary

Evofem Biosciences, Inc. announced that it has received $1.5 million in funding from Keystone Capital Partners LLC, Cavalry Fund I Management, LLC, Mercer Street Capital Partners, LLC, Seven Knots, LLC, Stratgyx, LLC, Walleye Capital LLC

Evofem Biosciences, Inc. announced delayed 10-Q filing

Nasdaq Stock Market to Delist the Common Stock of Evofem Biosciences, Inc

Evofem Biosciences, Inc. Announces Resignation of Alexander A. Fitzpatrick as the General Counsel and Secretary

Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women

Evofem Biosciences Announces Approval of Phexxi in Nigeria

Evofem Biosciences, Inc.(OTCPK:EVFM) dropped from S&P TMI Index

Evofem Biosciences Receives A Written Notice from the Nasdaq Hearings Panel to Delist the Company’s Securities

Price target decreased to US$2.31

Evofem Biosciences, Inc. Affirms 2022 Guidance

Evofem Biosciences, Inc. Appoints Jenny Yip to Board of Directors

Evofem Biosciences, Inc. Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 Evoguard Trial Evaluating Phexxi for the Prevention of Chlamydia and Gonorrhea in Women

Evofem Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling

Evofem partners with a360 Media to support Phexxi prescription growth

Consensus forecasts updated

Evofem announces peer-reviewed publication on birth control method

Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier

Consensus forecasts updated

Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent from United States Patent and Trademark Office

Evofem announces U.S. patent win for birth control method

Evofem Biosciences, Inc. Announces Results of A Post Hoc Analysis of the Registrational Phase 3 AMPOWER trial investigating the ability of Phexxi

Evofem Biosciences, Inc. Announces U.S. Food and Drug Administration Extended the Shelf Life of Phexxi from Three to Four Years

Consensus forecasts updated

Price target decreased to US$19.75

Evofem Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $26.6 million.

Price target increased to US$35.00

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Evofem Biosciences, Inc. Announces Phexxi in the Phase 3 AMPOWER Clinical Trial

Price target increased to US$35.00

Evofem Biosciences, Inc. Announces Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem's Phase 3 AMPOWER Clinical Trial

Price target increased to US$2.33

Evofem Biosciences, Inc. to Report Q1, 2022 Results on May 04, 2022

Nasdaq Accepts Evofem Biosciences Plan to Regain Listing Compliance

Evofem Biosciences, Inc. Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women At the 2022 Academy of Managed Care Pharmacy Annual Meeting

Evofem Biosciences, Inc., Annual General Meeting, May 04, 2022

Evofem Completes Enrollment in EVOGUARD Phase 3 Clinical Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target increased to US$2.33

Evofem Biosciences, Inc. to Report Q4, 2021 Results on Mar 03, 2022

U.S. Food and Drug Administration Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences

Evofem: ACA Coverage Of Phexxi Is A Game Changer

President recently bought US$51k worth of stock

Evofem Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Evofem Biosciences, Inc. Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Independent Chairman William Hall has left the company

Ödemelerde İstikrar ve Büyüme